Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -5% Improvement Relative Risk ICU admission -9% Hospitalization -36% Recovery -2% post-hoc primary Recovery, cough 13% Recovery, tachypnea 17% Viral clearance -23% c19ivermectin.com Rezai et al. IRCT20111224008507N4 Ivermectin RCT EARLY Favors ivermectin Favors control
Rezai, 549 patient ivermectin early treatment RCT: 9% higher ICU admission [p=0.95], 36% higher hospitalization [p=0.41], 2% worse recovery [p=0.49], and 23% worse viral clearance [p=0.16] https://c19p.org/rezai3
copied to clipboard
Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials
Rezai et al., Frontiers in Medicine, doi:10.3389/fmed.2022.919708
16 Jun 2022    Source   PDF   Share   Tweet
RCT 549 low risk outpatients in Iran. Reported outcomes are very different from the pre-specified outcomes [irct.ir]. The inpatient trial is listed separately.
The pre-specified primary clinical outcome was not reported. The reported components of this outcome are both positive.
Pre-specified outcomes (3 not reported) [irct.ir]:
- reduction in persistent cough and tachypnea and O2 saturation above 94% - not reported
- negative PCR - reported
- main complaints recovery time - not reported (only individual symptoms)
- hospitalization - reported
- time to hospitalization - not reported
- mortality - reported
- side effects - reported in only one patient (anomalous)
A new outcome "relative recovery" is reported but not mentioned in the trial registration. The reported percentages and RR do not match.
Authors include a researcher caught on video admitting that conclusions on ivermectin research were influenced by a funder [c19ivermectin.com].
Most/many patients were also treated with famotidine, vitamin C, vitamin D, and zinc, limiting room for improvement.
Authors indicate bottles were identical, but tablets were only similar.
Ivermectin was obtained from Alborz Daru Co.
risk of death, 4.9% higher, RR 1.05, p = 1.00, treatment 1 of 268 (0.4%), control 1 of 281 (0.4%).
risk of ICU admission, 9.0% higher, RR 1.09, p = 0.95, treatment 268, control 281.
risk of hospitalization, 36.0% higher, RR 1.36, p = 0.41, treatment 268, control 281.
risk of no recovery, 2.0% higher, RR 1.02, p = 0.49, treatment 268, control 281, post-hoc primary outcome.
risk of no recovery, 13.2% lower, RR 0.87, p = 0.09, treatment mean 3.87 (±0.18) n=268, control mean 4.46 (±0.18) n=281, cough.
risk of no recovery, 16.7% lower, RR 0.83, p = 0.81, treatment mean 2.5 (±0.51) n=268, control mean 3.0 (±0.92) n=281, tachypnea.
risk of no viral clearance, 23.5% higher, RR 1.23, p = 0.16, treatment 268, control 281.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta analysis: multiple critical issues, see study page.
Rezai et al., 6/16/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, Middle East, peer-reviewed, mean age 35.5, 29 authors, study period 19 February, 2021 - 30 August, 2021, dosage 400μg/kg days 1-3, trial IRCT20111224008507N4.
Contact: drmsrezaii@yahoo.com.
All Studies   Meta Analysis
This PaperIvermectinAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit